Home Metabolic Retatrutide (30mg) Metabolic Research Peptide GLP-1 / GIP / Glucagon triple-receptor agonist Research-grade, Australia In stock dispatched Australia-wide View & buy on store Retatrutide (development code LY3437943) is a synthetic triple-agonist peptide that acts on three metabolic receptor targets at once: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
Our formulations are evaluated for real-world performance, ensuring that they deliver results as promised
Serious Side Effects and When to Contact a Provider Serious side effects are uncommon, but medical guidance is important if you experience: Severe or persistent abdominal pain Ongoing vomiting Signs of dehydration such as confusion or minimal urination Symptoms of low blood sugar, including shakiness, sweating, or rapid heartbeat Prompt communication with your provider helps prevent complications
be wary of any company claiming to have compounded GLP-1 drugs that are FDA-approved
The obesity indication timeline remains less certain
For commercially insured patients: Wegovy or Zepbound with a manufacturer savings card at $25 per fill
